Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model

BACKGROUND: Immunochemotherapy, the combined use of immunotherapy and chemotherapy, has demonstrated great promise in several cancers. LTX-315 is an oncolytic peptide with potent immunomodulatory properties designed for the local treatment of solid tumors. By inducing rapid immunogenic cell death th...

Descripción completa

Detalles Bibliográficos
Autores principales: Camilio, Ketil A., Wang, Meng-Yu, Mauseth, Brynjar, Waagene, Stein, Kvalheim, Gunnar, Rekdal, Øystein, Sveinbjørnsson, Baldur, Mælandsmo, Gunhild M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343247/
https://www.ncbi.nlm.nih.gov/pubmed/30670061
http://dx.doi.org/10.1186/s13058-018-1092-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343247/
https://www.ncbi.nlm.nih.gov/pubmed/30670061
http://dx.doi.org/10.1186/s13058-018-1092-x

Ejemplares similares